PY-Alo

PY-Alo (0.25-8 μM; 24 h) inhibits the viability of ovarian cancer SKOV3, A2780, and A2780/DDP cells with IC₅₀ values of 2.57, 2.34, and 2.89 μM, respectively, while showing lower toxicity to normal ovarian SKOV3 cells with an IC₅₀ of 7.21 μM^[1].

PY-Alo (3.0-5.0 μM; 30 min-24 h) accumulates in the nuclear DNA of A2780/DDP cells and induces γ-H2AX DNA damage^[1].
PY-Alo (1.0 μM; 24 h) exhibits activity in A2780/DDP cells by synergizing with Cisplatin (HY-17394) and reducing the viability of DDP-resistant cells^[1].
PY-Alo (3.0 μM; 24 h) inhibits cell migration and invasion in A2780 and A2780/DDP cells, disrupts mitochondrial function (increases intracellular Ca²⁺, ROS, and Mito-ROS while decreasing MMP) and redox homeostasis (decreases intracellular ATP and GSH levels), induces apoptosis and autophagy (increases the Bax/Bcl-2 ratio and the protein expression levels of p53, Cleaved Caspase-9/3, LC3B II, and p62), induces mitochondrial structural damage, and induces autolysosome formation^[1].
PY-Alo (3.0 μM; 24 h) downregulates the mRNA expression levels of mitochondrial respiratory chain complex core subunits in A2780/DDP cells^[1].

PY-Alo (10.0 μM) selectively binds dsDNA with a binding constant of 3.46 × 10⁵ M^−1[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.